AbbVie Inc vs Burlington Stores Inc — how do they compare? AbbVie Inc trades at $248.48 (market cap $441.94B), while Burlington Stores Inc trades at $359.51 (market cap $22.59B). The key difference: AbbVie Inc is far larger — about 19.6× Burlington Stores Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Burlington Stores Inc pays none. Which is the better fit depends on your goals.
| ABBV | BURL | |
|---|---|---|
Market Cap | $441.94B | $22.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $263.58 | $372.19 |
52-Week Low | $197.38 | $242.43 |
Enterprise Value | $506.19B | $27.71B |
Dividend Yield | 2.77% | — |
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.
Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →